Press releases // 02 December 2015
IntegraGen Collaborating with FIRE-3 Clinical Trial Investigators to Study hsa-miR-31-3p Metastatic Colorectal Cancer Biomarker
IntegraGen announced a collaboration with investigators from the FIRE-3 clinical trial (AIO KRK-0306) to further study the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR effect in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy.